Efficacy of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations

医学 分裂情感障碍 精神科 抗精神病药 置信区间 氯丙嗪 急诊医学 精神分裂症(面向对象编程) 内科学 精神病
作者
Pragya Thaman,Caitlin E. Kulig,Daniel Greer
出处
期刊:Journal of Clinical Psychopharmacology [Lippincott Williams & Wilkins]
被引量:2
标识
DOI:10.1097/jcp.0000000000001810
摘要

Abstract Purpose/Background Schizophrenia is a chronic, debilitating mental illness that incurs a large economic burden. Decreasing hospital readmissions is a priority in health care to improve patient quality of life and decrease health care costs. Determining ways to prevent readmissions such as improving access to long-acting injectable (LAI) antipsychotics is important to assess. Methods/Procedures A single-center retrospective review was conducted comparing readmission rates of patients diagnosed with schizophrenia or schizoaffective disorder discharged on LAI or oral antipsychotics between August 1, 2019, and June 30, 2022. The primary outcome was the 30-day psychiatric readmission rate. Secondary outcomes included chlorpromazine equivalent doses and use of anticholinergic medications. Findings/Results The 30-day readmission rate was 1.9% for the LAI antipsychotic group and 8.3% for the oral antipsychotic group ( P = 0.03; 95% confidence interval, 1.05–20.02). The average chlorpromazine equivalent antipsychotic dose of patients discharged on LAI versus oral antipsychotic medications was 477.3 and 278.6 mg/d, respectively ( P < 0.001). In addition, the prevalence of medications used to treat extrapyramidal symptom was 22.3% (n = 23) for the LAI antipsychotic group and 30.8% (n = 74) for the oral antipsychotic group ( P = 0.12). Sixty-four percent of LAI antipsychotics utilized were obtained from pharmaceutical company hospital inpatient free trial programs. Implications/Conclusions Long-acting injectable antipsychotics showed a statistically significant reduction in 30-day rehospitalizations as compared with oral antipsychotics and hospital inpatient free trial programs aided in LAI antipsychotic acquisition.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
馥日祎发布了新的文献求助100
刚刚
陈惠123发布了新的文献求助10
刚刚
yuanjingnan发布了新的文献求助10
刚刚
anzi完成签到,获得积分10
1秒前
1秒前
1秒前
Hello的应助被Liareve采纳,获得10
2秒前
2秒前
尘归尘完成签到,获得积分10
2秒前
Ashore发布了新的文献求助10
3秒前
所所的应助被闪闪的绿旋采纳,获得10
3秒前
Jasper的应助被wydkyd采纳,获得30
3秒前
DF完成签到,获得积分10
4秒前
4秒前
小马甲的应助被瓦伦泰采纳,获得10
4秒前
zmy完成签到 ,获得积分10
5秒前
11111发布了新的文献求助10
6秒前
新晋学术小生完成签到 ,获得积分10
6秒前
6秒前
334niubi666完成签到 ,获得积分10
7秒前
yuanjingnan完成签到,获得积分10
7秒前
QAQ发布了新的文献求助10
8秒前
花花完成签到,获得积分10
8秒前
Dan发布了新的文献求助10
8秒前
chunfengfusu发布了新的文献求助10
8秒前
程伊森发布了新的文献求助10
9秒前
aaa完成签到,获得积分10
9秒前
9秒前
xz完成签到 ,获得积分10
11秒前
11秒前
1618发布了新的文献求助10
11秒前
12秒前
搜集达人的应助被xtc采纳,获得10
13秒前
zorro3574完成签到,获得积分10
16秒前
16秒前
踏实的盼柳的应助被WaNgBO采纳,获得10
16秒前
16秒前
17秒前
BANANA发布了新的文献求助10
17秒前
王乐安完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158017
求助须知:如何正确求助?哪些是违规求助? 9553900
关于积分的说明 21716555
捐赠科研通 7747340
什么是DOI,文献DOI怎么找? 3426934
关于科研通互助平台的介绍 2551639
邀请新用户注册赠送积分活动 2471005